318 related articles for article (PubMed ID: 15231037)
1. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system.
Govindarajan R; Nagarsenker MS
J Pharm Pharmacol; 2004 Jun; 56(6):725-33. PubMed ID: 15231037
[TBL] [Abstract][Full Text] [Related]
2. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
3. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin.
Sridevi S; Chauhan AS; Chalasani KB; Jain AK; Diwan PV
Pharmazie; 2003 Nov; 58(11):807-10. PubMed ID: 14664337
[TBL] [Abstract][Full Text] [Related]
5. Dissolution properties and characterization of halofantrine-2-hydroxypropyl-beta-cyclodextrin binary systems.
Onyeji CO; Omoruyi SI; Oladimeji FA
Pharmazie; 2007 Nov; 62(11):858-63. PubMed ID: 18065103
[TBL] [Abstract][Full Text] [Related]
6. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of supercritical fluid technology as preparative technique of benzocaine-cyclodextrin complexes--comparison with conventional methods.
Al-Marzouqi AH; Jobe B; Dowaidar A; Maestrelli F; Mura P
J Pharm Biomed Anal; 2007 Jan; 43(2):566-74. PubMed ID: 17010552
[TBL] [Abstract][Full Text] [Related]
8. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-beta-cyclodextrin ternary system.
Mura P; Bettinetti GP; Cirri M; Maestrelli F; Sorrenti M; Catenacci L
Eur J Pharm Biopharm; 2005 Jan; 59(1):99-106. PubMed ID: 15567306
[TBL] [Abstract][Full Text] [Related]
9. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
Fathy M; Sheha M
Pharmazie; 2000 Jul; 55(7):513-7. PubMed ID: 10944779
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
12. Physical-chemical characterization of binary and ternary systems of ketoprofen with cyclodextrins and phospholipids.
Cirri M; Maestrelli F; Mennini N; Mura P
J Pharm Biomed Anal; 2009 Dec; 50(5):683-9. PubMed ID: 19095391
[TBL] [Abstract][Full Text] [Related]
13. Binary and ternary inclusion complexes of finasteride in HPbetaCD and polymers: preparation and characterization.
Asbahr AC; Franco L; Barison A; Silva CW; Ferraz HG; Rodrigues LN
Bioorg Med Chem; 2009 Apr; 17(7):2718-23. PubMed ID: 19282187
[TBL] [Abstract][Full Text] [Related]
14. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes.
Ruan LP; Yu BY; Fu GM; Zhu DN
J Pharm Biomed Anal; 2005 Jul; 38(3):457-64. PubMed ID: 15925247
[TBL] [Abstract][Full Text] [Related]
15. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes.
Cirri M; Rangoni C; Maestrelli F; Corti G; Mura P
Drug Dev Ind Pharm; 2005 Aug; 31(7):697-707. PubMed ID: 16207617
[TBL] [Abstract][Full Text] [Related]
16. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
[TBL] [Abstract][Full Text] [Related]
17. Solid-state flurbiprofen and methyl-β-cyclodextrin inclusion complexes prepared using a single-step, organic solvent-free supercritical fluid process.
Rudrangi SR; Kaialy W; Ghori MU; Trivedi V; Snowden MJ; Alexander BD
Eur J Pharm Biopharm; 2016 Jul; 104():164-70. PubMed ID: 27163245
[TBL] [Abstract][Full Text] [Related]
18. Enhanced solubility and bioavailability of flurbiprofen by cycloamylose.
Baek HH; Kwon SY; Rho SJ; Lee WS; Yang HJ; Hah JM; Choi HG; Kim YR; Yong CS
Arch Pharm Res; 2011 Mar; 34(3):391-7. PubMed ID: 21547670
[TBL] [Abstract][Full Text] [Related]
19. Influence of the preparation method on the physical-chemical properties of ketoprofen-cyclodextrin-phosphatidylcholine ternary systems.
Cirri M; Maestrelli F; Mennini N; Mura P
J Pharm Biomed Anal; 2009 Dec; 50(5):690-4. PubMed ID: 19097721
[TBL] [Abstract][Full Text] [Related]
20. Effect of water-soluble polymers on naproxen complexation with natural and chemically modified beta-cyclodextrins.
Faucci MT; Mura P
Drug Dev Ind Pharm; 2001 Oct; 27(9):909-17. PubMed ID: 11763468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
